福安藥業(300194.SZ):美國二級子公司完成註冊登記
格隆匯12月2日丨福安藥業(300194.SZ)公佈,2019年11月15日,公司第四屆董事會第十次會議審議通過了《關於在美國設立二級子公司的議案》,同意公司全資子公司福安藥業集團寧波天衡製藥有限公司在美國設立子公司,設立目的主要為推進與Red Realty LLC《股權購買和增資協議》的實施,同時進一步開拓國際業務。
近日,美國二級子公司在內華達州完成註冊登記,註冊名稱:Fuan Tianheng(USA),LLC。
上述二級子公司的註冊設立,將有利於公司進一步加快推進與Red Realty LLC《股權購買和增資協議》的實施和相關業務的開展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.